http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005065239-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6c3a9161887743e8b65ded8ce23a3354 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e2b553bc097a02e761ccdcd3a5b40b6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7cc4ec15066bcb4a32630a3208e1d6a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bbadc41aa91592752369d88100f96411 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-1075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-1077 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-96 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-505 |
| filingDate | 2004-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87f7bc28945316562cadbe2b5735698c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab3ad22523c4dd2e5bbc7dc0af95124f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e41f918dd9fbace931e0d446f5294037 |
| publicationDate | 2005-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2005065239-A2 |
| titleOfInvention | Novel recombinant proteins with n-terminal free thiol |
| abstract | The present invention relates to novel modified proteins having N-terminal free thiols that can be produced by recombinant methods and are ready for further chemical derivatization. In particular, the invention relates to erythropoietin conjugate compounds having altered biochemical, physiochemical and pharmacokinetic properties. More particularly, one embodiment of the invention relates to erythropoietin conjugate compounds of the formula: (M)n-X-A-cys-EPO (I) where EPO is an erythropoeitin moiety selected from erythropoietin or an erythropoietin variant having at least one amino acid different from the wild-type human EPO, or any pharmaceutical acceptable derivatives thereof having biological properties of causing bone marrow cells to increase production of red blood cells; cys represents the amino acid cysteine and occurs at position -1 relative to the amino acid sequence of the erythropoietin moiety; A indicates the structure of the residual moiety used to chemically attach X to the thiol group of -1Cys; X is a water soluble polymer such as a polyalkylene glycol or other polymer; M is an organic molecule (including peptides and proteins) that increases the circulating half-life of the construct; and N is an integer from 0 to 15. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015032981-A1 |
| priorityDate | 2003-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 637.